Skip to main content
SpringerLink
Log in

Molecular Imaging in Schizophrenia

  • Protocol
  • First Online:
Book cover Molecular Imaging in the Clinical Neurosciences

Part of the book series: Neuromethods ((NM,volume 71))

  • 1014 Accesses

Abstract

Schizophrenia is a severe mental illness diagnosed on the basis of particular symptoms and characterised by a fluctuating time course. Its pathophysiology is incompletely understood and this has hampered the development of new drug treatments. It has proven challenging to produce convincing animal models of the illness, which has also limited the development of new treatments. These two factors highlight the value of PET and SPECT imaging for research in the disorder in providing in vivo measures of brain function and relating this to clinical features and outcome. PET imaging can be applied to study regional variation in neural activity at rest or during performance of cognitive tasks that are impaired in schizophrenia. A major application of PET imaging in schizophrenia is the use of neuroreceptor measures. Several methodological factors warrant particular consideration in PET studies of schizophrenia. In particular, the role of partial volume effects, movement and the clinical heterogeneity of the disorder. Whilst it is not always possible to avoid these effects, there are approaches to minimising their effects, such as partial volume and movement correction. There are also a number of common potential confounding factors that warrant consideration—in particular the effect of current and prior exposure to medications and other psychoactive drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645

    Article  PubMed  Google Scholar 

  2. Rossler W, Salize HJ, van Os J, Riecher-Rossler A (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15:399–409

    Article  PubMed  Google Scholar 

  3. Lewis DA, Gonzalez-Burgos G (2006) Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12:1016–1022

    Article  PubMed  CAS  Google Scholar 

  4. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S (2009) Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 15:2550–2559

    Article  PubMed  CAS  Google Scholar 

  5. Howes OD, McDonald C, Cannon M, Arseneault L, Boydell J, Murray RM (2004) Pathways to schizophrenia: the impact of environmental factors. Int J Neuropsychopharmacol 7(Suppl 1):S7–S13

    Article  PubMed  CAS  Google Scholar 

  6. Andreasen NC, O’Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD (1997) Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349:1730–1734

    Article  PubMed  CAS  Google Scholar 

  7. Hazlett EA, Buchsbaum MS (2001) Sensorimotor gating deficits and hypofrontality in schizophrenia. Front Biosci 6:D1069–D1072

    Article  PubMed  CAS  Google Scholar 

  8. Hazlett EA, Buchsbaum MS, Jeu LA, Nenadic I, Fleischman MB, Shihabuddin L, Haznedar MM, Harvey PD (2000) Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr Res 43:33–46

    Article  PubMed  CAS  Google Scholar 

  9. Parsey RV, Mann JJ (2003) Applications of positron emission tomography in psychiatry. Semin Nucl Med 33:129–135

    Article  PubMed  Google Scholar 

  10. Mannell MV, Franco AR, Calhoun VD, Canive JM, Thoma RJ, Mayer AR (2010) Resting state and task-induced deactivation: a methodological comparison in patients with schizophrenia and healthy controls. Hum Brain Mapp 31:424–437

    PubMed  Google Scholar 

  11. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426–445

    Article  PubMed  CAS  Google Scholar 

  12. Desco M, Gispert JD, Reig S, Sanz J, Pascau J, Sarramea F, Benito C, Santos A, Palomo T, Molina V (2003) Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Res 122:125–135

    Article  PubMed  Google Scholar 

  13. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Desco M, Palomo T (2005) Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl) 178:17–26

    Article  CAS  Google Scholar 

  14. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK (2007) Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 51:s13–s18

    Article  PubMed  Google Scholar 

  15. Kumakura Y, Cumming P (2009) PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 15:635–650

    Article  PubMed  CAS  Google Scholar 

  16. Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Grunder G (2007) Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 27:8080–8087

    Article  PubMed  CAS  Google Scholar 

  17. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, Cunningham VJ, Grasby PM (2009) The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 33:1109–1132

    Article  PubMed  CAS  Google Scholar 

  18. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451

    Article  PubMed  CAS  Google Scholar 

  19. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569–2574

    Article  PubMed  CAS  Google Scholar 

  20. Laruelle M, Abi-Dargham A (1999) Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13:358–371

    Article  PubMed  CAS  Google Scholar 

  21. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767

    PubMed  CAS  Google Scholar 

  22. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56–72

    Article  PubMed  CAS  Google Scholar 

  23. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104–8109

    Article  PubMed  CAS  Google Scholar 

  24. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231–239

    Article  PubMed  CAS  Google Scholar 

  25. Abi-Dargham A, Giessen EV, Slifstein M, Kegeles LS, Laruelle M (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65(12):1091–1093

    Article  PubMed  CAS  Google Scholar 

  26. Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB (2010) D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage 50:1402–1407

    Article  PubMed  CAS  Google Scholar 

  27. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM (2010) Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 30:1682–1706

    Article  PubMed  CAS  Google Scholar 

  28. Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219

    Article  PubMed  CAS  Google Scholar 

  29. Zakzanis KK, Hansen KT (1998) Dopamine D2 densities and the schizophrenic brain. Schizophr Res 32:201–206

    Article  PubMed  CAS  Google Scholar 

  30. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211–221

    PubMed  CAS  Google Scholar 

  31. Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355–371

    Article  PubMed  CAS  Google Scholar 

  32. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60:319–346

    Article  PubMed  CAS  Google Scholar 

  33. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S (2009) The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:1078–1086

    Article  PubMed  CAS  Google Scholar 

  34. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J (2006) D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85:232–244

    Article  PubMed  Google Scholar 

  35. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024–1031

    Article  PubMed  CAS  Google Scholar 

  36. Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761–767

    Article  PubMed  Google Scholar 

  37. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708–3719

    PubMed  CAS  Google Scholar 

  38. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634–636

    Article  PubMed  CAS  Google Scholar 

  39. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M (2007) In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9:117–125

    Article  PubMed  Google Scholar 

  40. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Article  PubMed  CAS  Google Scholar 

  41. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520

    Article  PubMed  CAS  Google Scholar 

  42. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340:199–202

    Article  PubMed  CAS  Google Scholar 

  43. Grunder G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Hartter S, Schreckenberger M, Stoeter P, Hiemke C, Rosch F, Wong DF, Bartenstein P (2006) The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31:1027–1035

    Article  PubMed  Google Scholar 

  44. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H (2007) Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 190:241–249

    Article  CAS  Google Scholar 

  45. Frankle WG, Narendran R, Huang Y, Hwang DR, Lombardo I, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2005) Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57:1510–1516

    Article  PubMed  CAS  Google Scholar 

  46. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvalahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157:269–271

    Article  PubMed  CAS  Google Scholar 

  47. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D’Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R (2000) Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47:371–379

    Article  PubMed  CAS  Google Scholar 

  48. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P (2011) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16(1):67–75

    Article  PubMed  CAS  Google Scholar 

  49. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267–271

    Article  PubMed  CAS  Google Scholar 

  50. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM (2006) Correction of head movement on PET studies: comparison of methods. J Nucl Med 47:1936–1944

    PubMed  Google Scholar 

  51. Rousset OG, Deep P, Kuwabara H, Evans AC, Gjedde AH, Cumming P (2000) Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson’s disease subjects. Synapse 37:81–89

    Article  PubMed  CAS  Google Scholar 

  52. Shidahara M, Tsoumpas C, Hammers A, Boussion N, Visvikis D, Suhara T, Kanno I, Turkheimer FE (2009) Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage 44:340–348

    Article  PubMed  Google Scholar 

  53. Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL, Bullmore E, Fox PT (2008) Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry 64(9):774–781

    Article  PubMed  Google Scholar 

  54. Tost H, Braus DF, Hakimi S, Ruf M, Vollmert C, Hohn F, Meyer-Lindenberg A (2010) Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat Neurosci 13:920–922

    Article  PubMed  CAS  Google Scholar 

  55. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K (2003) Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306:1145–1151

    Article  PubMed  CAS  Google Scholar 

  56. Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28:787–794

    Article  PubMed  Google Scholar 

  57. Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, Muller MJ, Bartenstein P, Grunder G (2006) Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30:1332–1339

    Article  PubMed  Google Scholar 

  58. Tiihonen J, Vilkman H, Rasanen P, Ryynanen OP, Hakko H, Bergman J, Hamalainen T, Laakso A, Haaparanta-Solin M, Solin O, Kuoppamaki M, Syvalahti E, Hietala J (1998) Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatry 3:156–161

    Article  PubMed  CAS  Google Scholar 

  59. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34:759–766

    Article  PubMed  CAS  Google Scholar 

  60. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegeles L, Talbot P, Evans S, Krystal J, Laruelle M, Abi-Dargham A (2005) Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58:779–786

    Article  PubMed  CAS  Google Scholar 

  61. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM (2007) The effect of nicotine on striatal dopamine release in man: a [(11)C]raclopride PET study. Synapse 61:637–645

    Article  PubMed  CAS  Google Scholar 

  62. Shergill SS, Brammer MJ, Williams SC, Murray RM, McGuire PK (2000) Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 57:1033–1038

    Article  PubMed  CAS  Google Scholar 

  63. McGuire PK, Shah GM, Murray RM (1993) Increased blood flow in Broca’s area during auditory hallucinations in schizophrenia. Lancet 342:703–706

    Article  PubMed  CAS  Google Scholar 

  64. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35:41–50

    Article  PubMed  CAS  Google Scholar 

  65. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13–20

    Article  PubMed  Google Scholar 

  66. Hariri AR, Weinberger DR (2003) Imaging genomics. Br Med Bull 65:259–270

    Article  PubMed  CAS  Google Scholar 

  67. Meyer-Lindenberg A, Weinberger DR (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818–827

    Article  PubMed  CAS  Google Scholar 

  68. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Hietala J, Cannon TD (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62:371–378

    Article  PubMed  CAS  Google Scholar 

  69. Hirvonen J, van Erp TG, Huttunen J, Nagren K, Huttunen M, Aalto S, Lonnqvist J, Kaprio J, Cannon TD, Hietala J (2006) Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res 146:13–20

    Article  PubMed  CAS  Google Scholar 

  70. Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004) Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 24:2825–2831

    Article  PubMed  CAS  Google Scholar 

  71. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 35:549–562

    Article  PubMed  Google Scholar 

  72. Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, Schmidt M, Gasparini F, Hock C, Buck A (2007) Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med 48:1207–1215

    Article  PubMed  CAS  Google Scholar 

  73. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167–174

    Article  PubMed  CAS  Google Scholar 

  74. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:1–11

    Article  PubMed  CAS  Google Scholar 

  75. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130–1131

    Article  PubMed  CAS  Google Scholar 

  76. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681–688

    Article  PubMed  CAS  Google Scholar 

  77. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61:134–142

    Article  PubMed  Google Scholar 

  78. Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Fujimura Y, Matsumoto R, Ota M, Takano A, Otsuka A, Yasuno F, Okubo Y, Kashima H, Suhara T (2009) Regional dopamine synthesis in patients with schizophrenia using L-[beta-(11)C]DOPA PET. Schizophr Res 108:78–84

    Article  PubMed  Google Scholar 

  79. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91:11651–11654

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Clinical Sciences Centre, Institute of Psychiatry, Imperial College, Hammersmith Hospital and King’s College, London, UK

    Oliver Howes

Authors
  1. Oliver Howes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Howes .

Editor information

Editors and Affiliations

  1. , Dept. of Psychiatry, Psychotherapy,, RWTH Aachen University, Pauwelsstr. 30, Aachen, 52074, Germany

    Gerhard Gründer

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this protocol

Cite this protocol

Howes, O. (2012). Molecular Imaging in Schizophrenia. In: Gründer, G. (eds) Molecular Imaging in the Clinical Neurosciences. Neuromethods, vol 71. Humana Press, Totowa, NJ. https://doi.org/10.1007/7657_2012_57

Download citation

  • DOI: https://doi.org/10.1007/7657_2012_57

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-988-4

  • Online ISBN: 978-1-61779-989-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation